PARP Inhibitor VIII, PJ34

Cell permeable: yes

Primary Target
PARP

Reversible: yes

Toxicity: Harmful (C)

A water-soluble phenanthridinone derivative that acts as a potent anti-inflammatory agent and a reversible inhibitor of poly(ADP-ribose) polymerase (PARP; EC₅₀ = 20 nM). Shown to be about 10,000-fold more potent than the prototypical PARP inhibitor, 3-Aminobenzamide (Cat. No. 165350) (EC₅₀ = 200 µM). Suppresses neutrophil infiltration and nitric oxide production in peritonitis. Does not act as an antioxidant even at higher concentrations (1 µM to 10 µM). PJ34 inhibits peroxynitrite-induced cell necrosis with an (EC₅₀ = 20 nM). Exhibits neuroprotective effects in in vivo and in vitro models of stroke. The solid form of this compound (Cat. No. 528150, 528151 ) is also available.

Abdelkarim, G.E., et al. 2001. Int. J. Mol. Med.7, 255.
Garcia-Soriano, F.G., et al. 2001. Nature Med.7, 108.
Mabley, G.J., et al. 2001. Inflamm. Res.50, 561.

Packaged under inert gas

A 20 mM (2 mg/301 µL) solution of PARP Inhibitor VIII, PJ34 (Cat. No. 528150) in H₂O.

Following initial thaw, aliquot and freeze (-70°C). Aliquots are stable for up to 6 months at -70°C.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany